Restore in-person dispensing requirements for the abortion pill
What the document says“As an interim step, the FDA should immediately restore the REMS by removing the in-person dispensing requirement to eliminate dangerous tele-abortion and abortion-by-mail distribution.”
The Risk Evaluation and Mitigation Strategy formerly required mifepristone to be dispensed in person. The chapter calls this an interim step, and asks separately for reporting of complications through the adverse event system and for transparency about inspections of the manufacturers.
What the document actually says“As an interim step, the FDA should immediately restore the REMS by removing the in-person dispensing requirement to eliminate dangerous tele-abortion and abortion-by-mail distribution.”
For now, the FDA should bring back the rule. It required the pill to be handed over in person.
One pill is used to end a pregnancy. It used to be handed over in person. Now it can be sent by mail. The book says the old rule should come back.
Read against the documents indexed here on August 26, 2026, and nothing was found that answers this. Nothing indexed restores the in-person dispensing requirement in the mifepristone risk evaluation and mitigation strategy, and no FDA action on that strategy appears in the record indexed here. The nearest candidate by wording, memo-2025-01907, tells federal employees to return to in-person work, which matched on the phrase alone. That is a record of a search, not a finding that nothing has happened: an act this site does not hold, or one that answers the proposal in words unlike its own, would not be caught by it.